Association of Partial Chromosome 3 Deletion in Uveal Melanomas With Metastasis-Free Survival - Archive ouverte HAL Access content directly
Journal Articles JAMA Ophthalmology Year : 2020

Association of Partial Chromosome 3 Deletion in Uveal Melanomas With Metastasis-Free Survival

(1, 2) , (3) , (4) , (4) , (3) , (5, 6) , (1, 5) , (7) , (8) , (2) , (9) , (1, 3) , (6, 4) , (4) , (1, 3) , (3)
1
2
3
4
5
6
7
8
9

Abstract

Importance: Studies on uveal melanomas (UMs) have demonstrated the prognostic value of 8q gain and monosomy 3, but the prognosis of UMs with partial deletion of chromosome 3 remains to be defined. Objective: To examine the association of partial chromosome 3 deletion in UMs with metastasis-free survival. Design, setting, and participants: This retrospective cohort study of 1088 consecutive comparative genomic hybridization arrays performed from May 1, 2006, to July 31, 2015, assessed patients presenting with UMs with and without partial loss of chromosome 3 at a referral center. Data analysis was performed from September 1, 2017, to November 30, 2017. Exposure: Uveal melanoma with or without partial loss of chromosome 3. Main outcomes and measures: Metastasis-free survival and overall survival at 60 months. Results: Of the 1088 consecutive comparative genomic hybridization arrays that were performed, 43 UMs (4.0%) in 43 patients (median age, 58 years [range, 12-79 years]; 22 [51%] female) carried partial deletions of chromosome 3. Median follow-up was 66 months (range, 1.2-126.2 months). Metastasis-free survival at 60 months was 33.6% (95% CI, 15.8%-71.4%) for UMs that carried a deletion of the BAP1 (BRCA1 associated protein 1) locus (BAP1del; 24 tumors) and 80.5% (95% CI, 64.8%-100%) for UMs without the loss of the BAP1 locus (BAP1 normal [BAP1nl]; 19 tumors) (log-rank P = .001). Overall survival at 60 months was 64.5% (95% CI, 43.5%-95.8%) in the BAP1del group vs 84.1% (95% CI, 69.0%-100%) in the BAP1nl group (log-rank P < .001). In these 43 cases, metastasis-free survival at 60 months was 100% for UMs without loss of the BAP1 locus or 8q gain, 70.0% (95% CI, 50.5%-96.9%) for UMs that carried 1 of these alterations, and 12.5% (95% CI, 2.1%-73.7%) for those that carried both (log-rank P < .001). Similarly, overall survival at 60 months was 100% for UMs without loss of the BAP1 locus or 8q gain, 80.8% (95% CI, 63.3%-100%) for UMs that carried 1 of these alterations, and 46.7% (95% CI, 23.3%-93.6%) for those that carried both (log-rank P < .001). Conclusions and relevance: These findings suggest that partial deletion of chromosome 3 encompassing the BAP1 locus is associated with poor prognosis. A cytogenetic classification of UMs could be proposed based on the status of the BAP1 locus instead of the chromosome 3 locus, while also taking chromosome 8q into account.
Fichier principal
Vignette du fichier
35461_2_merged_1571561518.pdf (788.06 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-03037871 , version 1 (03-12-2020)

Identifiers

Cite

Manuel Rodrigues, Khadija Ait Rais, Flore Salviat, Nathalie Algret, Fatoumata Simaga, et al.. Association of Partial Chromosome 3 Deletion in Uveal Melanomas With Metastasis-Free Survival. JAMA Ophthalmology, 2020, 138 (2), pp.182. ⟨10.1001/jamaophthalmol.2019.5403⟩. ⟨inserm-03037871⟩
31 View
41 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More